RxSight RXST 深 沪
已收盘 07-17 16:00:00 美东时间
5.55
-0.020
-0.36%
华盛通- 最 高5.725
- 今 开5.48
- 成交量 83.92万股
- 最 低 5.38
- 昨 收 5.57
- 总市值 2.30亿
- 52周最高 13.22
- 市盈率 静 --
- 换手率 2.03%
- 52周最低 4.48
- 委 比 88.23%
- 总股本 4139.66万
- 历史最高 66.54
- 量 比 0.79
- 振 幅 6.19%
- 历史最低 4.48
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RxSight appoints new CEO
RxSight (RXST) appointed Aziz Mottiwala as president and chief executive officer, effective July 20, 2026. Mottiwala succeeds Ron Kurtz, M.D., who will remain with the company as chief medical officer...
07-16 04:18
RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron Kurtz
RxSight, Inc. (NASDAQ:RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
07-16 04:16
律所对RxSight发起调查，涉及2025年业绩披露引发股价暴跌
Glancy Prongay Wolke & Rotter LLP宣布对眼科医疗设备公司RxSight启动调查，关注董事会是否违反了对股东的信托义务...
07-11 03:41
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Needham Reiterates Buy on RxSight, Maintains $11 Price Target
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $11 price target.
07-07 18:06
Swiss stocks - Factors to watch on July 7
Swiss stocks - Factors to watch on July 7 ZURICH/GDANSK, July 7 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: COMPANY STATEMENTS ALCON AG ALCC.S The Swiss eyecare company on Monday announced a collaboration with the American company RxSight RXST.O for the dev
07-07 12:51
RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M Est
RxSight (NASDAQ:RXST) sees Q2 sales of $32.000 million-$34.000 million vs $32.077 million analyst estimate.
07-07 04:50
RxSight Raises FY2026 Sales Guidance from $120.000M-$135.000M to $140.000M-$160.000M vs $129.250M Est
RxSight (NASDAQ:RXST) raises FY2026 sales outlook from $120.000 million-$135.000 million to $140.000 million-$160.000 million vs $129.250 million estimate.
07-07 04:50
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
RxSight ( ($RXST) ) has provided an announcement. On June 30, 2026, RxSight ent...
07-07 04:47
CORRECTED-RxSight says Q2 results hit by more widespread competitive trialing
CORRECTED-RxSight says Q2 results hit by more widespread competitive trialing Corrects throughout to report total revenue figures, instead of sales figures that the company includes as one part of total revenue; the story was previously corrected to remove an extraneous word in the headline Overview
07-07 04:35
